Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
十八味诃子丸 (18-Ingredient Terminalia Pills) is a traditional Tibetan medicine (藏药) formulated as a red-brown water pill. It is developed and manufactured by companies such as Diqing Shangri-La Blue Lapis Lazuli Tibetan Cultural Development and is marketed under the brand name '神水藏药'. The formulation consists of 18 natural ingredients, with *Terminalia chebula* (Hezi) as the principal component, alongside other herbs like red flower, cardamom, and Swertia. Its primary therapeutic actions are clearing kidney heat and reducing inflammation. It is indicated for the treatment of urinary tract infections, hematuria, lumbar sprains, kidney-related lower back pain, hip pain, and dorsal foot edema. As a multi-herb traditional medicine, it lacks a single defined molecular target in Western pharmacology and is regulated as a Chinese patent medicine (中成药) under approval number Z20023246.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 十八味诃子丸.